New drug 9MW3811 passes first safety check in healthy volunteers
NCT ID NCT05740475
First seen Jan 04, 2026 · Last updated May 25, 2026 · Updated 24 times
Summary
This early-stage study tested a single dose of a new drug called 9MW3811 in 32 healthy adults to see if it is safe and how the body processes it. The drug is being developed for lung scarring (pulmonary fibrosis) and tumors, but this study did not involve patients with those conditions. The main goal was to check for side effects and measure drug levels in the blood.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Scientia Clinical Research
Randwick, New South Wales, Australia
Conditions
Explore the condition pages connected to this study.